Sign inJoin waitlistJoin the waitlist

Jared Weiss

Executive Board Member

Credentials: · · · ·

History

Present

University of Pennsylvania
Beth Israel Deadoness Medical Center, Harvard
Yale University School of Medicine
2004
Brown University

Research

Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase…
The Lancet Oncology · 2016 · 1,435 citations
Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012…
Journal of Clinical Oncology · 2016 · 701 citations
Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer
New England Journal of Medicine · 2020 · 650 citations

Bhishamjit Chera
22 papers
Juneko Grilley-Olson
22 papers
Neil Hayes
17 papers
Trevor Hackman
17 papers
MW
Mark Weissler
15 papers
Shetal Patel
15 papers
Liza Villaruz
13 papers
AZ
Adam Zanation
11 papers
Colette Shen
11 papers
Samip Patel
11 papers
Corey Langer
10 papers
Siddharth Sheth
10 papers

Clinical trials

Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC
Principal investigator · Recruiting · Phase 1
UNC Lineberger Comprehensive Cancer Center
2024–2028
Abequolixron (RGX-104) and Durvalumab in Lung Cancer
Principal investigator · Terminated · Phase 1
UNC Lineberger Comprehensive Cancer Center
2024–2025
Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer
Principal investigator · Recruiting · Early phase 1
UNC Lineberger Comprehensive Cancer Center
2023–2029
Study of Trilaciclib and Lurbinectidin
Principal investigator · Recruiting · Phase 2
UNC Lineberger Comprehensive Cancer Center
2022–2028